TARRYTOWN, N.Y.--(BUSINESS WIRE)--March 15, 2006--Progenics Pharmaceuticals, Inc., (NASDAQ: PGNX) today announced its results of operations for the fourth quarter and year ended December 31, 2005. Revenues for the fourth quarter ended December 31, 2005 totaled $2.0 million compared to $3.3 million for the same quarter in 2004. For the year ended December 31, 2005, Progenics reported total revenues of $9.5 million compared to $9.6 million for the comparable period in 2004. Revenues primarily reflect payments received by the Company for contract work performed for PSMA Development Company LLC, the Company’s joint venture regarding PSMA technology, and funding from government grants and contracts.
